MedCity News

DECEMBER 12, 2024

The post ASH 2024 Recap: Movement in Multiple Myeloma, Cell Therapy, Sickle Cell Disease & More appeared first on MedCity News. A multiple myeloma cell therapy has encouraging results analysts say could make it best in its class and a gene-editing therapy is showing early promise in sickle cell disease.

Biopharma 246

Biopharma Pharma 246

Fierce Pharma

JANUARY 8, 2024

In it’s annual Firepower report, EY says the biopharma industry enters 2024 with the capability and motivation to increase M&A activity. The late surge of activity in 2023 also bodes well for a 2024 uptick, the group said. Morgan Healthcare Conference. |

Prospecting 224

Prospecting Biopharma Pharma Healthcare 224

Fierce Pharma

DECEMBER 22, 2023

And it is with cautious optimism that industry watchers see the trend continuing in 2024. . | Even with the Federal Trade Commission keeping a watchful eye on the biopharma industry and the economic landscape giving some players pause, mergers and acquisitions are back on the rise.

Biopharma 323

Biopharma 323

Fierce Pharma

JULY 30, 2024

For the first time since its sales peaked during the pandemic, Pfizer registered year-over-year revenue growth during the second quarter of 2024. For more than a year after Pfizer’s COVID product sales peaked at the end of 2022, the company’s quarterly revenues showed year-over-year declines. |

Sales 267

Sales 267

PharmaVoice

OCTOBER 28, 2024

Big Pharma CEOs are hedging all bets by supporting both sides of the aisle in the 2024 election.

Pharma 306

Pharma 306

Fierce Pharma

MARCH 27, 2024

WuXi Biologics stays the course with positive 2024 outlook as national security crackdown threatens business in US fkansteiner Wed, 03/27/2024 - 13:12

242

242

Fierce Pharma

FEBRUARY 8, 2024

This week on “The Top Line,” we explore the most anticipated drug launches of 2024. This week on “The Top Line,” we explore the most anticipated drug launches of 2024.

Sales 189

Sales Pharma Marketing 189

MedCity News

NOVEMBER 6, 2023

The biotech is preparing to advance its drug to Phase 3 testing in 2024. Celldex drug barzolvolimab has mid-stage results in a chronic inflammatory skin disease that top those of an approved Genentech drug and two experimental Novartis therapies.

Pharma 307

Pharma Biopharma 307

Fierce Pharma

NOVEMBER 22, 2024

As other Big Pharmas face local headwinds, Pfizer doubles down on China commitment with Zai Lab antimicrobial marketing pact fkansteiner Fri, 11/22/2024 - 09:04

Marketing 207

Marketing Pharma 207

MedCity News

DECEMBER 20, 2023

GSK gains rights to a Hansoh Pharma antibody drug conjugate that targets a protein abundant on lung cancer cells and other types of solid tumors. The pharmaceutical giant plans to start its own slate of clinical trials with this ADC in 2024.

Pharma 304

Pharma Pharmaceutical Biopharma 304

Fierce Pharma

SEPTEMBER 7, 2023

Analysts anticipate that the trend will continue in 2023 and into 2024 as companies attempt to beef up their portfolios. Biopharma M&A is on an uptick compared to the post-pandemic doldrums of the last two years. Biopharma M&A is on an uptick compared to the post-pandemic doldrums of the last two years.

Biopharma 304

Biopharma Pharma 304

Fierce Pharma

APRIL 11, 2024

As lawmakers, biopharma companies and others try to stabilize vulnerable pharma supply chains, drug shortages have become about as bad as they’ve ever been in the U.S. | as of 2024’s first quarter—the highest number recorded since ASHP began tracking shortage data back in 2001.

Biopharma 297

Biopharma Pharma 297

Fierce Pharma

MAY 2, 2024

WuXi Biologics has withdrawn from the 2024 BIO International Convention as the U.S. . | Japan's Ono will buy kinase inhibitor expert Deciphera for $2.4 Novartis invests further in radiopharmaceuticals with two deals. grows hostile against certain Chinese biotech companies. And more.

Pharma 183

Pharma Pharmaceutical 183

PharmaVoice

JANUARY 12, 2024

From regulatory concerns to leadership skills, pharma leaders at JPM shared how they’re approaching the coming year.

Pharma 195

Pharma 195

Fierce Pharma

JANUARY 23, 2024

Ahead of key Stelara patent cliff, J&J's pharma business churns out growth fkansteiner Tue, 01/23/2024 - 11:32

Pharma 194

Pharma 194

Fierce Pharma

JANUARY 3, 2024

Expect more of the same in 2024, according to a report from Evaluate, which places Novo and Lilly in the top two spots for global new sales.

Sales 259

Sales Biopharma Leads Marketing 259

Fierce Pharma

AUGUST 30, 2024

ESC 2024: UK's George Medicines posts positive results for triple-combo blood pressure drug on heels of FDA submission fkansteiner Fri, 08/30/2024 - 15:54

Medicine 210

Medicine FDA 210

PharmaVoice

DECEMBER 20, 2024

The high drama of an election year, industry layoffs, patent cliff strategies and other key trends that shaped pharma in 2024.

Pharma 147

Pharma 147

MedCity News

OCTOBER 2, 2023

Novartis’s iptacopan met the first of two main goals in its pivotal study in immunoglobulin A nephropathy, and the pharma giant plans to seek accelerated FDA approval next year. The drug could challenge two available therapies for the rare kidney disorder.

FDA 274

FDA Pharma Biopharma 274

Fierce Pharma

JANUARY 19, 2023

Bluebird extends cash runway to late 2024 with $113M raise through stock sale esagonowsky Thu, 01/19/2023 - 08:30

Sales 224

Sales 224

Fierce Pharma

OCTOBER 29, 2024

As the 2024 U.S. This week on "The Top Line," we explore how each presidential candidate’s approach to drug pricing could shape future policy.

181

181

World of DTC Marketing

SEPTEMBER 6, 2021

SUMMARY: Those working in pharma know that ageism exists, especially in the sales force. Pharma has been purging older employees for some time, and when you reach the magic age of 50+, you’re going to be pushed to take “early retirement.” She hired an attorney and is now in litigation with the top 10 pharma companies.

Pharma 219

Pharma Sales Physicians Education 219

Fierce Pharma

OCTOBER 2, 2024

Sitting down with Emily Keith, SVP at AdTheorent Health, at Digital Pharma East 2024, we explored the cutting-edge int | Sitting down with Emily Keith, SVP at AdTheorent Health, at Digital Pharma East 2024, we explored the cutting-edge intersection of healthcare, advertising and privacy.

Pharma 153

Pharma Healthcare Healthcare 153

Fierce Pharma

JANUARY 4, 2024

In 2024, CDMOs can advance their priorities on three fronts, a group of experts said during a recent Evaluate webinar on the state of the industry. Even after the heady highs of the COVID-19 era, the contract development and manufacturing organization (CDMO) realm remains one of biopharma's buzziest fields.

Biopharma 253

Biopharma Manufacturing 253

Fierce Pharma

SEPTEMBER 19, 2024

In this week's episode of "The Top Line," we’re recapping and discussing the major trends from Digitial Pharma East, w | In this week's episode of "The Top Line," we’re recapping and discussing the major trends from Digitial Pharma East.

Pharma 130

Pharma 130

Fierce Pharma

OCTOBER 22, 2024

With multiple high-profile production pacts already in the books for 2024, CDMO Samsung Biologics has hooked another big one. Following a string of high-profile deals, Samsung Biologics has locked down a $1.2 billion contract with an unnamed Asia-based pharmaceutical company that’s expected to run through December 2037.

Pharmaceutical 245

Pharmaceutical 245

PharmaVoice

OCTOBER 14, 2024

Long-time executives with a strong track record of advancing drug R&D, business savvy strategies and leadership in various sectors of pharma.

Pharma 195

Pharma 195

Fierce Pharma

FEBRUARY 1, 2024

On both fronts, Sanofi expects to see dividends in 2024. . | As Sanofi strives to become a global immunology leader, it's also busy making the most of a crucial respiratory launch with partner AstraZeneca.

238

238

Fierce Pharma

SEPTEMBER 20, 2024

Fierce Pharma Asia—Merck's collabs with Daiichi, Eisai deliver readouts; Granules hit with FDA manufacturing observations aliu Fri, 09/20/2024 - 09:21

Manufacturing 169

Manufacturing Pharma FDA 169

Fierce Pharma

JANUARY 31, 2024

But the British pharma major says that the successful launch represents just one round of a boxing match, and much is still to be decided, especially with Moderna expected to join the battle in 2024. billion in sales in 2023 compared to $890 million for Pfizer's Abrysvo.

Sales 290

Sales Pharma 290

PharmaVoice

FEBRUARY 16, 2024

Belt tightening and streamlined portfolios are critical in 2024 amid continued economic uncertainty.

Pharma 216

Pharma 216

PM360

NOVEMBER 2, 2023

Don’t miss your chance to vote for the winners of the 2024 Pharma Choice Awards. Voting will remain open until Dec.

Pharma 98

Pharma 98

Fierce Pharma

JANUARY 9, 2023

JPM23: Bluebird touts gene therapy launch progress, extends cash runway to 2024. esagonowsky. Mon, 01/09/2023 - 09:26.

190

190

Fierce Pharma

SEPTEMBER 12, 2023

Xspray Pharma, before receiving an FDA slapdown in July, had expected to launch its competitor to Bristol Myers Squibb’s leukemia blockbuster Sprycel within the second half of 2023. 1, 2024, or potentially earlier under certain circumstances. 1, 2024, or potentially earlier under certain circumstances. 28, 2026.

FDA 262

FDA Pharma 262

Fierce Pharma

JULY 1, 2024

Welcome to Fierce Pharma's regulatory tracker for the second half of 2024. | In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications.

Pharma 205

Pharma FDA Marketing 205

Fierce Pharma

JULY 25, 2024

While manufacturing and supply hitches have troubled the rollout of Sanofi’s key respiratory syncytial virus (RSV) drug, the near-term expected approval of a pair of new filling lines is giving the | While manufacturing and supply hitches have troubled the rollout of Sanofi’s key respiratory syncytial virus drug, the near-term expected approval of (..)

Sales goal 226

Sales goal Manufacturing Sales Pharma 226

European Pharmaceutical Review

JANUARY 2, 2024

According to results from a survey by GlobalData, the top challenges for the pharmaceutical industry in 2024 will be inflation, geopolitical conflict and drug pricing pressures. Data outcomes revealed that most respondents from Pharma considered that drug pricing and reimbursement constraints will have a negative impact in 2024.

Pharma 102

Pharma Medicine Marketing Government 102